Pathologic complete response after neoadjuvant immunochemotherapy: Persistent recurrence risk highlights the need for stratified management

Journal:

Journal of Thoracic and Cardiovascular Surgery

Published:

2026-02-26

DOI:

10.1016/j.jtcvs.2026.02.017

Affiliations:

26

Authors:

30

Go to article

Institutions	Authors	Share
State Key Laboratory of Metabolic Dysregulation and Prevention and Treatment of Esophageal Cancer, China	4.000000	0.13
Cancer Institute and Hospital, CAMS & PUMC, China	2.000000	0.07
Zhongshan Hospital, Fudan University, China	1.000000	0.03
Fourth Hospital of Hebei Medical University, China	1.000000	0.03
Hunan Cancer Hospital, China	1.000000	0.03
Harbin Medical University Cancer Hospital, China	1.000000	0.03
Fujian Cancer Hospital, China	1.000000	0.03
Fujian Medical University Union Hospital, China	1.000000	0.03
Sichuan Cancer Hospital, China	1.000000	0.03
West China School of Medicine/West China Hospital of Sichuan University (WCSM/WCH), SCU, China	1.000000	0.03
The First Affiliated Hospital of Nanchang University, China	1.000000	0.03
Tangdu Hospital, China	1.000000	0.03
First Affiliated Hospital, ZZU, China	1.000000	0.03
Anyang Tumor Hospital, China	1.000000	0.03
Henan Provincial People's Hospital, China	1.000000	0.03
Zhejiang Cancer Hospital (ZJCH), China	1.000000	0.03
The Affiliated Huaian No.1 People's Hospital, NJMU, China	1.000000	0.03
Shantou Central Hospital, China	1.000000	0.03
Qilu Hospital of Shandong University, China	1.000000	0.03
Liaoning Cancer Hospital and Institute, China	1.000000	0.03
Affiliated Jinling Hospital, NJU, China	1.000000	0.03
Zhongnan Hospital, WHU, China	1.000000	0.03
The First Affiliated Hospital of Xi'an Jiaotong University, XJTU, China	1.000000	0.03
Shanxi Cancer Hospital, China	1.000000	0.03
The First Affiliated Hospital, USTC, China	1.000000	0.03
Beijing Cancer Hospital / School of Oncology, PKUHSC, China	1.000000	0.03

Interested in Oncology and Carcinogenesis?